A look at the deconditioning cascade that starts when regular exercise stops — and how hard it is to fight your way back to ...
A new letter to the editor challenges a transcriptomic study linking collagen-rich extracellular matrix to postoperative ...
Zacks Investment Research on MSN
SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy
Solventum Corporation SOLV recently received FDA 510(k) clearance for the combined use of its Restrata Synthetic Electrospun ...
A 2026 review proposes that SFRP4 may inhibit tumor angiogenesis through integrin-linked disruption of Wnt–β-catenin ...
As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary ...
Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) ...
CROWN ctDNA data link early lorlatinib progression to genomic complexity, TP53 and bypass pathways rather than new ALK ...
Arcus Biosciences casdatifan combinations showed superior or competitive PFS and response rates versus historical benchmarks.
BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative ...
Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit's license territories, ...
Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit’s AI-powered pathology platform, for tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results